David Epstein – AfricaNewsAnalysis

Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU

24/01/2014 ANA 0

Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure by the Committee for Medicinal Products for Human […]

Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV

07/10/2013 ANA 0

Novartis announced recently results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis[1]. Enbrel is a current standard-of-care anti-TNF medication […]

Novartis to reveal landmark Phase III results from specialty dermatology portfolio at upcoming EADV 2013 congress

30/09/2013 ANA 0

Novartis announced today that new Phase III results from its expanding specialty dermatology portfolio will be presented at the 22nd Congress of the European Association of Dermatology and Venereology (EADV), taking place in Istanbul, Turkey, […]

FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure

24/06/2013 ANA 0

Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to RLX030 (serelaxin), an investigational treatment for patients with acute heart failure (AHF). The FDA has concluded that […]

World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease

29/05/2013 ANA 0

Today Novartis is joining the global multiple sclerosis (MS) community in celebration of World MS Day by launching a new campaign and participating in initiatives that encourage information and experience exchange around MS. Novartis is […]